4
Changes in Ownership
Allogene Therapeutics, Inc. Filed Acc 0001209191-19-019762
Chief Financial Officer acquired 49,400 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| SCHMIDT ERIC THOMAS Chief Financial Officer | 2019-03-13 | Grant or award | +49,400 | 49,400 | D: show line 1 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| SCHMIDT ERIC THOMAS Chief Financial Officer | 2019-03-13 | Grant or award · Employee Stock Option (Right to Buy) | +83,500 | 83,500 | D: show line 2 in the form |
Loading xslF345X03/doc4.xml…